Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer

Inclusion Criteria: * Age ≥ 50 years and ≤ 75 years * Life expectancy \>10 years * Localized prostatic adenocarcinoma and histologically proven * Intermediate risk cancer(T2b or PSA between 10 and 20 or Gleason = 7(3+4) according to Amico criteria * Metastasis or pelvic pathologic ganglion (≥ 10 mm) absence * OMS \< 2 * No previous treatment by radiotherapy and/or curietherapy * Hormonotherapy authorized before and during the study * Rectal or uretero-vesical pathology * Signed informed consent * Social security system affiliation * Individual deprived of liberty or placed under the authority of a tutor. * No anesthesia contraindication Exclusion Criteria: * Adenocarcinoma not histologically proven * Metastases presence * Pathological nodes presence(≥ 10 mm) * Prior prostate endoscopic resection * history of other malignancy except for appropriately treated superficial basal cell skin cancer * Medical contraindications to anesthesia * Patients with uncontrolled psychiatric disease or medical disease incompatible with the protocol * Impossibility to respect the medical follow-up of the protocol for geographical, social or psychic reasons